INTRODUCTION
The number of people aged C65 years is increasing, and currently represents approximately 13.0% of the US population. At the same time, the incidence and prevalence of diagnosed type 2 diabetes mellitus (T2DM) among adults aged C65 years have increased to values of 2.7% annually and 24.8%, respectively [1] . Persons aged C65 years diagnosed with T2DM in the US have morbidity and mortality rates far in excess of their counterparts without diabetes, including microvascular complications and cardiovascular disease [2] .
In the UK Prospective Diabetes Studies, treatment with antihyperglycemic therapies reduced the risk of microvascular and, in the metformin arm, macrovascular disease endpoints among patients with newly diagnosed T2DM [3, 4] . Importantly, this early treatment led to sustained benefits related to the development and progression of microvascular disease as well as to emergent risk reduction in macrovascular disease and all-cause mortality [5] . The American Diabetes Association (ADA) and the European Association for the Study of Diabetes recommend initiating treatment with metformin, in combination with lifestyle changes, immediately after the diabetes diagnosis, with a target hemoglobin A 1c (HbA 1c ) value of \7.0% for adults [6] . The American Geriatrics Society also recommends a target HbA 1c of B7.0% for relatively healthy, older adults [7] . However, specific glycemic targets may need to be re-evaluated for higherrisk patients with T2DM in light of the increased mortality observed in patients aggressively treated with antihyperglycemic agents to achieve intensive glucose lowering glycemic targets [8] .
However, many patients aged C65 years are not prescribed antihyperglycemic agents after diagnosis of T2DM. In a US employer-based health insurance data set, 44.0% of individuals aged C65 years received no antihyperglycemic therapy in the 12-month period following T2DM diagnosis [9] . Similarly, in a retrospective US cohort study, older patients (age C65 years) with newly diagnosed T2DM were less likely to have oral antihyperglycemic therapy initiated following diagnosis than younger patients [10] . Among patients who showed disease progression in a 1-year followup period (defined as a HbA 1c increase from \7.0 to C7.0%), the likelihood of initiating antihyperglycemic therapy decreased by 40.0% with every decade increase in age [11] .
Although there have been studies of physicians' attitudes toward recommending lifestyle changes after a diagnosis of T2DM [12, 13] 
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Patient Characteristics
Complete information was provided by participating physicians for 770 older patients with T2DM not treated with antihyperglycemic therapy for at least 6 months following diagnosis (Table 1) . These patients had a mean (±SD) age of 72 (6) 
Physicians' Reasons for Non-Treatment with Antihyperglycemic Agent
The frequency of selection of each physician's reason for non-treatment is shown in Table 2 .
When evaluated by category of reasons, the ''diet and exercise'' category was selected most (92.5%) followed by ''mild hyperglycemia'' 
Stratum
The ''diet and exercise'' category was the first-ranked reason for non-treatment in all HbA 1c strata, with a decrease in selection with increasing HbA 1c levels (Fig. 1) . In addition, while ''mild hyperglycemia'' was cited as the first-ranked reason category for non-treatment by physicians for 27.0% of patients with a most recent HbA 1c \7.0%, it was also the first-ranked reason for 19.0% with an HbA 1c of 7.0-7.4%, and 13.0% with an HbA 1c C7.5% (Fig. 1) . In contrast, ''patient's concerns'', ''concerns related to antihyperglycemic agents'', or ''comorbidities and polypharmacy'' tended to be selected as the first-ranked reason category for non-treatment by physicians for more patients with higher
HbA 1c values (Fig. 1) .
Reasons Selected for Non-Treatment by Patient Characteristics or Comorbid Conditions
Physicians appeared to select reasons (using all reasons analysis) within ''concerns related to antihyperglycemic agents'' or ''comorbidities and polypharmacy'' categories more often for patients with pre-existing microvascular complications, cardiovascular conditions, renal impairment (i.e., eGFR \60 mL/min/1.72 m 2 ), or already taking more than three medications. Duration of diabetes above the median (i.e., [12 months) did not appear to impact selected reasons (Fig. 2) . 
Physician-Stated
DISCUSSION
This survey of over 500 US primary care physicians examined their reasons for not initiating antihyperglycemic treatment in older patients who had not been treated for at least 6 months following diagnosis of T2DM. The characteristics of the present cohort of patients were generally similar to those of a selected their first-ranked reason for not initiating antihyperglycemic therapy from the ''mild hyperglycemia'' category (the ''diet and exercise'' category was not a standalone category in this survey) for their older and younger patients with newly diagnosed T2DM [19] .
The proportion of physicians selecting reasons related to ''diet and exercise,'' or ''mild hyperglycemia'' as reasons for non-treatment with antihyperglycemic agents tended to decline as the patients' HbA 1c values increased.
Although these reasons may have been appropriate for patients with a most recent HbA 1c value \7.0%, selection of these reasons continued for many untreated patients whose most recent HbA 1c value was C7.0%. For patients whose most recent HbA 1c level was C7.0%, physicians tended to select patient-centric reasons for not initiating glycemic therapy in the present study. The most-selected reasons within the ''patient's concerns'' category were related to taking additional medications, fear of side effects, including hypoglycemia and weight gain, and increased financial burden. In the aforementioned UK survey by Zhang et al. [19] , general practitioners were more likely to select reasons related to side effects, disease or medication burden for patients, and well-being of the patient for their older patients compared to younger ones. Interestingly, ''not wanting to take additional medication'' was behind only ''try diet and exercise'' as a first-ranked reason for not initiating therapy in the present study. Although patient fear or physician concern of the common side effects with antihyperglycemic agents (e.g., hypoglycemia, weight gain, gastrointestinal intolerance, and fluid retention) was selected as reasons by approximately 17.0-30.0% of physicians, none of these reasons were selected by more than 1.0% of physicians as a first-ranked reason. This is in agreement with the findings of Grant et al. [20] , who reported that a patient's tendency to complain about side effects was not a major consideration when initiating antihyperglycemic therapy.
Consistent with the main reasons for not initiating an antihyperglycemic agent (diet and exercise, and mild hyperglycemia) observed in this study, physicians generally report that lifestyle change was a key component of diabetes treatment. However, physicians have also indicated that it was difficult for patients to change their lifestyle or diet [12, 13] .
In response to a questionnaire given to healthcare providers in Finland regarding a lifestyle change, almost all (98.0%) physicians reported that lifestyle change was always or nearly always a central part of treatment [13] .
Most (83.0%) reported that the biggest barrier to treatment of diabetes was always or nearly always the patients' unwillingness to change their lifestyle [13] . Likewise, most (87.0%) doctors in Denmark, responding to a questionnaire regarding a change in patient diet, thought that changing their diabetic patients' food habits was difficult or very difficult [12] . Furthermore, the proportion of T2DM patients treated with diet alone was positively associated with the level of their There is a paucity of evidence regarding the factors that influence the initiation of oral antihyperglycemic agents in clinical practice. Pani et al. [11] found that, despite disease progression in untreated patients with T2DM, the likelihood of initiating therapy was lower as the patient's age increased. In an observational study of US patients with newly diagnosed T2DM, age C65 years was a significant factor for not initiating oral antihyperglycemic therapy after adjusting for baseline and timevarying covariates [10] . In newly diagnosed T2DM patients C40 years of age, general practitioners tended to set the goal of normoglycemia for patients who were younger and in better overall health at diagnosis [21] .
Conversely, age does not always appear to be a major factor for initiating therapy in untreated patients with T2DM. In 603 newly diagnosed T2DM patients from a Dutch town, the time to first treatment with an oral antihyperglycemic agent was shortest in patients with the highest fasting plasma glucose values at the time of diagnosis, whereas age, body weight, and history of cardiovascular disease did not influence the initiation of therapy [22] . Grant et al. [20] This study has several limitations. The survey was developed and approved by experts, but no external validation was performed. To limit selection bias, physicians were instructed to select a patient on the basis of a randomly In conclusion, in this survey study of physicians, two-thirds of patients had appropriate glycemic control (i.e., HbA 1c \7.0%) and selection of reasons for nontreatment with antihyperglycemic agents related to this appears to be an appropriate clinical decision for many of these patients. The data from the present study also indicate that, in 
